The DTP vaccines market consists of sales of vaccines used for the treatment of diphtheria, tetanus, and pertussis (whooping cough) and related services by entities (organizations, sole traders and partnerships) that produce vaccines for diphtheria, tetanus, and pertussis (whooping cough). The different types of vaccines available for these diseases include DTaP (diphtheria, tetanus, and acellular pertussis) vaccine, DT (diphtheria and tetanus) vaccine, Tdap (combined tetanus, diphtheria and acellular pertussis) vaccine and Td (tetanus and diphtheria) vaccine. The market consists of revenue generated by the companies manufacturing DTP vaccines by the sales of these products.
The global DTP vaccines market is expected to decline from $4.19 billion in 2019 to $3.94 billion in 2020 at a compound annual growth rate (CAGR) of -6.02%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $4.80 billion in 2023 at a CAGR of 6.8%.